Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

This is primarily a relative-value signal inside obesity, not a fresh growth thesis. VKTX now has to clear a much higher bar because the market is no longer paying for mechanism novelty; it is paying for either best-in-class efficacy, meaningfully better tolerability, or a faster path to combination convenience. That structurally favors LLY and NVO, whose obesity franchises already have platform depth and can absorb incremental data without needing it to be transformative.

The immediate setup for VKTX is asymmetric to the downside if early human data are merely "good": pre-revenue biotech multiples compress fast when the story shifts from "could be first" to "one of several." The real catalyst path is 1-3 months around safety/PK and early pharmacodynamic read-through; if discontinuation or nausea signal issues emerge, dilution risk re-enters quickly. Over 6-18 months, the key falsifier for the bearish read is a clean tolerability profile plus clear appetite suppression that suggests the program can be paired rather than replaced.

Contrarian: the market may still be underpricing how large the combination-therapy market can get if payers accept better adherence over absolute weight-loss leadership. VKTX does not need to beat LLY/NVO head-to-head to matter, but it likely needs a cleaner profile than consensus assumes for a late entrant. Absent that, this looks more like an option on future M&A than a standalone fundamental winner.